Certain medications containing valsartan, a drug to treat high blood pressure, could contain a second substance that can cause cancer, Health Canada says.
All drugs containing valsartan, manufactured by Zhejiang Huahai Pharmaceuticals in China, were recalled in Canada after a first impurity, N-nitrosodimethylamine (NDMA), was identified earlier this summer. NDMA is classified as a probable human carcinogen, which means long-term exposure could increase the risk of cancer, according to regulators.
Drugs containing valsartan treat high blood pressure and help prevent heart attacks and stroke. They are also used by patients who have had heart failure or a recent heart attack.